Arcus Biosciences (RCUS) EBIT (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBIT of -$134.0 million for Q1 2026, down 9.84% year-over-year from -$148.6 million in Q1 2025, and down 17.54% quarter-over-quarter from -$114.0 million in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) EBIT (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBIT history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.
- In Q1 2026, EBIT fell 9.84% year-over-year to -$134.0 million; the TTM figure through Mar 2026 stood at -$398.0 million (up 8.72% YoY), while the FY2025 annual figure was -$386.0 million, down 16.97% from the prior year.
- EBIT for Q1 2026 stood at -$134.0 million, down from -$114.0 million in the prior quarter.
- The five-year high for EBIT was -$8.0 million in Q2 2025, with the low at -$142.0 million in Q3 2025.
- The 5-year median for EBIT is -$86.0 million (2023), against an average of -$86.5 million.
- Peak annual rise in EBIT reached 92.45% in 2025, while the deepest fall reached 662.5% in 2025.
- Arcus Biosciences' EBIT stood at -$74.0 million in 2022, then decreased by 22.97% to -$91.0 million in 2023, then slipped by 13.19% to -$103.0 million in 2024, then dropped by 10.68% to -$114.0 million in 2025, then decreased by 17.54% to -$134.0 million in 2026.
- Business Quant data shows RCUS's EBIT at -$134.0 million in Q1 2026, -$114.0 million in Q4 2025, and -$142.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -96.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -96.00 Mn |
| Mar 31, 2026 | -134.00 Mn |
| Dec 31, 2025 | -114.00 Mn |
| Sep 30, 2025 | -142.00 Mn |
| Jun 30, 2025 | -8.00 Mn |
| Mar 31, 2025 | -122.00 Mn |
| Dec 31, 2024 | -103.00 Mn |
| Sep 30, 2024 | -105.00 Mn |
| Jun 30, 2024 | -106.00 Mn |
| Mar 31, 2024 | -16.00 Mn |
| Dec 31, 2023 | -91.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -83.00 Mn |
| Mar 31, 2023 | -86.00 Mn |
| Dec 31, 2022 | -74.00 Mn |
| Sep 30, 2022 | -70.00 Mn |
| Jun 30, 2022 | -69.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 281.02 Mn |
| Sep 30, 2021 | -78.14 Mn |